Your browser doesn't support javascript.
loading
Structural Progression in Patients with Definite and Non-Definite Arrhythmogenic Right Ventricular Cardiomyopathy and Risk of Major Adverse Cardiac Events.
Aljehani, Areej; Baig, Shanat; Kew, Tania; Kalla, Manish; Sommerfeld, Laura C; Murukutla, Vaishnavi Ameya; Fabritz, Larissa; Steeds, Richard P.
Afiliación
  • Aljehani A; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK.
  • Baig S; Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth, Birmingham B15 2GW, UK.
  • Kew T; Echocardiography Cardiovascular Technology (ECVT) Program, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia.
  • Kalla M; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK.
  • Sommerfeld LC; Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth, Birmingham B15 2GW, UK.
  • Murukutla VA; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK.
  • Fabritz L; Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth, Birmingham B15 2GW, UK.
  • Steeds RP; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Biomedicines ; 12(2)2024 Jan 31.
Article en En | MEDLINE | ID: mdl-38397930
ABSTRACT
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare inherited disease characterised by early arrhythmias and structural changes. Still, there are limited echocardiography data on its structural progression. We studied structural progression and its impact on the occurrence of major adverse cardiovascular events (MACE). In this single-centre observational cohort study, structural progression was defined as the development of new major or minor imaging 2010 Task Force Criteria during follow-up. Of 101 patients, a definite diagnosis of ARVC was made in 51 patients, while non-definite 'early' disease was diagnosed in 50 patients. During 4 years of follow-up (IQR 2-6), 23 (45%) patients with a definite diagnosis developed structural progression while only 1 patient in the non-definite (early) group gained minor imaging Task Force Criteria. Male gender was strongly associated with structural progression (62% of males progressed structurally, while 88% of females remained stable). Patients with structural progression were at higher risk of MACE (64% of patients with MACE had structural progression). Therefore, the rate of structural progression is an essential factor to be considered in ARVC studies.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido